After an exhaustive search of literature, the American Academy of Ophthalmology has indicated that anti-VEGF treatment delivered by intravitreal injection, is safe and effective for wet macular degeneration for up to 2 years for Macugen treatments and 1 year for Lucentis treatments. The evidence examined suggests that vision improvements with Lucentis treatments are superior to those with Macugen treatments. However, evidence did not suggest a difference in safety between the two macular degeneration treatments.
There was evidence to support that Avastin treatments for macular degeneration may be safe and effective, but there was no endorsement given. Avastin has not been approved by the FDA for use in the eye.